SCHEMBL15840751

SCHEMBL15840751

Cc1nc(Nc2nc(=O)cc(CSc3ccc(Cl)cc3)[nH]2)nc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.62
ALDH1A1 P00352 8/20 0.62
SMN1; SMN2 Q16637 4/20 0.51
LMNA P02545 4/20 0.51
PAX8 Q06710 2/20 0.51
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ALPL P05186 2/20 0.48
ALPI P09923 1/20 0.48
ALPG P10696 1/20 0.48
EZH2 Q15910 1/20 0.47
KDM4E B2RXH2 1/20 0.47
KMT2A Q03164 4/20 0.47
AURKA O14965 1/20 0.45
HTT P42858 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
STAT3 P40763 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15840591 0.90 MAPT (0.55) MAPTALDH1A1SMN1; SMN2LMNAPAX8
SCHEMBL2495430 0.79 MAPK1 (0.57) MAPTALDH1A1SMN1; SMN2LMNAPAX8
SCHEMBL15840696 0.76 MAPT (0.58) MAPTALDH1A1SMN1; SMN2LMNAPAX8
SCHEMBL15840782 0.73 MAPT (0.49) MAPTALDH1A1SMN1; SMN2LMNAPAX8
SCHEMBL22853723 0.68 HSD17B10 (0.51) MAPTALDH1A1SMN1; SMN2LMNAPAX8
SCHEMBL15840836 0.68 MAPT (0.71) MAPTALDH1A1SMN1; SMN2LMNAPAX8
SCHEMBL15840668 0.67 MAPT (1.00) MAPTALDH1A1SMN1; SMN2LMNAPAX8
SCHEMBL15840692 0.67 MAPT (0.73) MAPTALDH1A1SMN1; SMN2LMNAPAX8
SCHEMBL31457434 0.67 HSD17B10 (0.52) MAPTALDH1A1SMN1; SMN2LMNAPAX8
SCHEMBL23657938 0.66 MAPK1 (0.57) MAPTALDH1A1SMN1; SMN2LMNAPAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 MAPT 1076/4885ALDH1A1 4348/4885SMN1; SMN2 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.